Cholesterol Support
Primary support
Arterosil® HP
Arterosil® HP is a proprietary blend of seaweed, fruit, and vegetable extracts that may support arterial and endothelial health.* The main bioactive component in Arterosil® HP is rhamnan sulfate (as MonitumRSTM), a polysaccharide extracted from a unique green seaweed, Monostroma nitidum, that may help support the endothelial glycocalyx.*
- Dosing: 2 capsules per day
- Duration: ongoing
RYR Synergy™
RYR Synergy™ is a synergistic blend of organic red yeast rice and coenzyme Q10 that may help support lipid and cholesterol metabolism.*
- Dosing: 2 capsules twice per day
- Duration: 3 months; re-evaluate biomarkers, signs, and symptoms
Niacin CRT™
Niacin CRT™ is a unique wax-matrix tablet that utilizes controlled-release technology (CRT). This technology delivers niacin at a continuous, controlled rate over a 6- to 8-hour period throughout the tablet’s transit time in the bowel, reducing the risk of flushing. This product is available in 500 mg and 750 mg tablets for greater flexibility in meeting nutritional needs.
- Dosing: 500–2,000 mg in divided doses; dose twice daily
- Duration: 3 months; re-evaluate biomarkers, signs, and symptoms
Secondary support
Annatto-E 300™
Annatto-E™ 300 is a unique tocopherol-free, tocotrienols-only product featuring tocotrienols sourced from the annatto tree. Annatto is a rich source of tocotrienols, containing 100% tocotrienols (90% delta and 10% gamma isomers) and no tocopherols. Annatto-E™ 300 contains 300 mg per softgel of delta/gamma tocotrienols.
- Dosing: 1 softgel per day
- Duration: 3 months; re-evaluate biomarkers, signs, and symptoms
BergaVin™
BergaVin™ features trademarked ingredients Bergavit® 40 bergamot and Vinia® red grape powder The polyphenols and flavonoids in bergamot and red grapes may support cholesterol metabolism* and antioxidant status, providing benefits that may further support coronary health.*
- Dosing: 2 capsules per day with a meal
- Duration: 3 months; re-evaluate biomarkers, signs, and symptoms
Disclaimer
*These statements have not been evaluated by the Food and Drug Administration. The Fullscript Integrative Medical Advisory team has developed or collected these templates from practitioners and supplier partners to help healthcare practitioners make decisions when building treatment plans. By adding this template to your Fullscript template library, you understand and accept that the recommendations in the template are for initial guidance and may not be appropriate for every patient.
Fullscript content philosophy
At Fullscript, we are committed to curating accurate, and reliable educational content for practitioners and patients alike. Our educational offerings cover a broad range of topics related to integrative medicine, such as supplement ingredients, diet, lifestyle, and health conditions.
Medically reviewed by expert practitioners and our internal Integrative Medical Advisory team, all Fullscript content adheres to the following guidelines:
- In order to provide unbiased and transparent education, information is based on a research review and obtained from trustworthy sources, such as peer-reviewed articles and government websites. All medical statements are linked to the original reference and all sources of information are disclosed within the article.
- Information about supplements is always based on ingredients. No specific products are mentioned or promoted within educational content.
- A strict policy against plagiarism is maintained; all our content is unique, curated by our team of writers and editors at Fullscript. Attribution to individual writers and editors is clearly stated in each article.
- Resources for patients are intended to be educational and do not replace the relationship between health practitioners and patients. In all content, we clearly recommend that readers refer back to their healthcare practitioners for all health-related questions.
- All content is updated on a regular basis to account for new research and industry trends, and the last update date is listed at the top of every article.
- Potential conflicts of interest are clearly disclosed.